Interviews with those who are working on the war against cancer. Brought to you by the ONCOassist team.
Oncology Spotlight
Claim This Podcastby Portable Medical Technology Ltd.
5.0(3 reviews)
33 episodes
Updated Weekly
Accepts GuestsHas SponsorsLocation 🇺🇸
59
Podcast Authority
BetaFairBased on show quality, social media presence, reviews, charts, and more
Quality64
Social0
YouTube76
Engagement60
Podcast Overview
Interviews with those who are working on the war against cancer. Brought to you by the ONCOassist team.
Language
🇺🇲
Publishing Since
6/9/2021
Unlock The Full Podcast Authority Score Report
See how your podcast performs across key metrics
59
Podcast Authority
BetaFairBased on show quality, social media presence, reviews, charts, and more
Quality64
Social0
YouTube76
Engagement60
9
Excellent Areas
1
Good Performance
9
Growth Opportunities
excellent
Episode Length
26 minutes
Performing excellently!
good
iTunes Tags
6.5/10
Recommendations available
Unlock the full report to see detailed tips
poor
Publishing Consistency
Every 53 days
Recommendations available
Unlock the full report to see detailed tips
+16 More Metrics
Unlock comprehensive insights including:
- • YouTube presence analysis
- • Social media reach metrics
- • RSS compliance scoring
- • Podcast 2.0 features
- • Technical standards
What's Included in Your Full Report
Detailed Analytics
- Complete breakdown of all 19 authority metrics
- Personalized recommendations for each metric
- Industry benchmarks and comparisons
- Technical RSS feed analysis and compliance scoring
Growth Strategies
- Step-by-step action plans for improvement
- Quick wins to boost your score immediately
- Pro tips from successful podcasters
Get your free podcast insights report
See how your show performs across every key metric
Instant delivery
No spam
Attract Better Guests
High authority scores make your podcast more attractive to industry leaders and influencers who want to appear on credible shows.
Secure Sponsorships
Sponsors look for podcasts with proven authority and engagement. Your score demonstrates your podcast's value to potential partners.
Grow Your Audience
Understanding your strengths and weaknesses helps you make data-driven decisions to expand your listener base effectively.
1 verified contact email on file for Oncology Spotlight
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
March 5, 2026
Expert Insights: ASCO GU 2026 - Key Takeaways from Studies with Dr. Yüksel Ürün
<p>👉 Visit https://oncoassist.com/ to streamline patient care with cutting-edge tools, treatment protocols, and calculators! </p><p><strong>🔬</strong>In this episode of Oncology Spotlight - Expert Insights, Dr Yüksel Ürün, medical oncologist at Ankara University, reviews key studies presented at the ASCO Genitourinary Cancers Symposium, 2026.</p><p>The discussion focuses on clinically relevant trial results across bladder cancer, kidney cancer, and metastatic prostate cancer, highlighting data that may influence treatment decisions in daily oncology practice.</p><p>Key Studies Discussed:• KEYNOTE-B15 trial – Enfortumab vedotin + pembrolizumab in muscle-invasive bladder cancer- <a href="https://www.asco.org/abstracts-presentations/256834" rel="ugc noopener noreferrer" target="_blank">https://www.asco.org/abstracts-presentations/256834</a></p><p> • LITESPARK-011 – Belzutifan + lenvatinib after IO therapy in kidney cancer - <a href="https://www.asco.org/abstracts-presentations/256659" rel="ugc noopener noreferrer" target="_blank">https://www.asco.org/abstracts-presentations/256659</a> </p><p> • LITESPARK-022 – Adjuvant belzutifan + pembrolizumab in high-risk kidney cancer - <a href="https://www.asco.org/abstracts-presentations/256660" rel="ugc noopener noreferrer" target="_blank">https://www.asco.org/abstracts-presentations/256660</a> </p><p> • BRCAAway trial – Abiraterone + olaparib combination in metastatic castration-resistant prostate cancer - <a href="https://www.asco.org/abstracts-presentations/256832" rel="ugc noopener noreferrer" target="_blank">https://www.asco.org/abstracts-presentations/256832</a> </p><p>Key Clinical Takeaways</p><p>✔ EV + pembrolizumab improves event-free survival in muscle-invasive bladder cancer ✔ Belzutifan combinations show promising activity in renal cell carcinoma ✔ Combination PARP inhibitor + ARPI therapy may significantly extend survival in selected mCRPC patients</p><p>A must-watch for oncologists and trainees looking for clear, clinically relevant takeaways from the latest GU oncology trials presented at ASCO GU26.</p><p><br /></p><p>📌 <strong>CHAPTERS & TIMESTAMPS</strong></p><p>🎙 <strong>00:08</strong> – Introduction</p><p>👨⚕️ <strong>00:14</strong> – Meet Dr. Yüksel Ürün</p><p>🧬 <strong>00:20</strong> – KEYNOTE-B15: EV + Pembrolizumab in Muscle-Invasive Bladder Cancer</p><p>📊 <strong>02:30</strong> – Event-Free Survival & Pathologic Response Results</p><p>⚕️ <strong>05:18</strong> – LITESPARK-011: Belzutifan + Lenvatinib in RCC</p><p>📈 <strong>06:20</strong> – Progression-Free Survival Improvement</p><p>💊 <strong>08:47</strong> – LITESPARK-022: Adjuvant Belzutifan + Pembrolizumab</p><p>📉 <strong>10:01</strong> – Disease-Free Survival Outcomes</p><p>🧪 <strong>11:34</strong> – BRCAAway Trial: PARP + ARPI Combination</p><p>📊 <strong>13:00</strong> – Survival Benefit in HRD-Mutated Prostate Cancer</p><p>🔬 <strong>15:16</strong> – Clinical Implications for Practice</p><p>👋 <strong>15:24</strong> – Closing Thoughts<br /></p><p>📢 JOIN THE CONVERSATION! ❓Drop your thoughts in the comments below!📲 Oncology at your fingertips.</p><p>Download the ONCOassist app:</p><p>📥 iOS: <a href="https://apple.co/4iuMxfS" rel="ugc noopener noreferrer" target="_blank">https://apple.co/4iuMxfS</a></p><p>📥 Android: <a href="https://bit.ly/oncoassistonandroid" rel="ugc noopener noreferrer" target="_blank">https://bit.ly/oncoassistonandroid</a></p><p>📥Webapp: <a href="https://bit.ly/ONCOassistOnWeb" rel="ugc noopener noreferrer" target="_blank">https://bit.ly/ONCOassistOnWeb </a></p><p>🚀 SUBSCRIBE to the ONCOassist Youtube Channel for more expert insights!🔔 Turn on notifications so you never miss an episode.</p><p>📌 FOLLOW US FOR UPDATES: </p><p>📍 LinkedIn: <a href="https://bit.ly/oncoassistlinkedin" rel="ugc noopener noreferrer" target="_blank">https://bit.ly/oncoassistlinkedin</a></p><p><br />📍 Twitter/X: <a href="https://bit.ly/oncoassisttwitter" rel="ugc noopener noreferrer" target="_blank">https://bit.ly/oncoassisttwitter</a></p>
February 17, 2026
Oncology Spotlight: Access, Equity & AI in Cancer Care with Dr. Shaqil Kassam
<p>👉 Visit https://oncoassist.com/ to streamline patient care with cutting-edge tools, treatment protocols, and calculators! </p><p><strong>🔬</strong>In this episode of Oncology Spotlight, Dr. Shaqil Kassam shares a powerful perspective from the front lines of community oncology in Canada.</p><p>From drug access delays in publicly funded systems to the real-world challenges of administering bispecific therapies outside academic centers, this conversation dives into the complexity of modern oncology.</p><p>We also explore:</p><ul><li><p>Community vs academic oncology – what truly differs?</p></li><li><p>The global equity gap in cancer care</p></li><li><p>How AI is already transforming clinic workflows and pathology</p></li><li><p>The real challenges behind sequencing new therapies</p></li><li><p>Why equitable access remains the biggest global barrier<br></p></li></ul><p> This is a must-watch for oncologists, trainees, and healthcare leaders navigating rapid innovation in constrained systems.</p><p><br></p><p>Check out the MedOncNow podcast: https://medoncnow.podbean.com/</p><p>📌 <strong>CHAPTERS & TIMESTAMPS</strong></p><p>🏥 <strong>00:00</strong> – The Biggest Issue: Drug Access in Public Healthcare</p><p>🎙️ <strong>00:36</strong> – Introduction & Guest Overview</p><p>👨⚕️ <strong>01:07</strong> – Dr. Kassam’s Journey to Medical Oncology</p><p>🌍 <strong>03:29</strong> – Community vs Academic Oncology Explained</p><p>📊 <strong>06:33</strong> – Are 80% of Patients Treated in Community Settings?</p><p>🤝 <strong>08:00</strong> – Collaboration Between Community & Academic Oncologists</p><p>🎧 <strong>08:44</strong> – The MedOncNow Podcast: Why It Started</p><p>💊 <strong>10:49</strong> – Practical Implementation of New Cancer Drugs</p><p>🌎 <strong>13:07</strong> – The Future of Oncology in Canada</p><p>⚖️ <strong>16:05</strong> – Equity: Canada’s Strength & Global Weakness</p><p>🌍 <strong>17:05</strong> – Barriers to Global Cancer Care</p><p>🧠 <strong>21:40</strong> – AI in Oncology: From Dictation to Digital Pathology</p><p>🎓 <strong>25:14</strong> – Advice for Future Oncologists</p><p><br></p><p>📢 JOIN THE CONVERSATION! ❓Drop your thoughts in the comments below!📲 Oncology at your fingertips.</p><p><br></p><p>Download the ONCOassist app:</p><p>📥 iOS: <a href="https://apple.co/4iuMxfS" target="_blank" rel="ugc noopener noreferrer">https://apple.co/4iuMxfS</a></p><p>📥 Android: <a href="https://bit.ly/oncoassistonandroid" target="_blank" rel="ugc noopener noreferrer">https://bit.ly/oncoassistonandroid</a></p><p>📥Webapp: <a href="https://bit.ly/ONCOassistOnWeb" target="_blank" rel="ugc noopener noreferrer">https://bit.ly/ONCOassistOnWeb </a></p><p><br></p><p>🚀 SUBSCRIBE to the ONCOassist Youtube Channel for more expert insights!🔔 Turn on notifications so you never miss an episode.</p><p><br></p><p>📌 FOLLOW US FOR UPDATES: </p><p><br></p><p>📍 LinkedIn: <a href="https://bit.ly/oncoassistlinkedin" target="_blank" rel="ugc noopener noreferrer">https://bit.ly/oncoassistlinkedin</a></p><p><br>📍 Twitter/X: <a href="https://bit.ly/oncoassisttwitter" target="_blank" rel="ugc noopener noreferrer">https://bit.ly/oncoassisttwitter</a></p>
January 6, 2026
Oncology Spotlight: Dr Shreyas Kalantri discusses Immunotherapy, Equity & Quality of Life
<p><strong>🔬</strong>In this episode, Dr. Shreyas Kalantri shares his journey from medical training in India to academic oncology in the United States, and reflects on what truly defines progress in cancer care.</p><p>The conversation dives deep into quality of life as a critical endpoint, disparities in immunotherapy access, the role of academic research, global oncology collaboration, and how AI can reshape oncology workflows. Dr. Kalantri also discusses his work with the HemOnc Fellows Network and ASCO’s Training & Early Career Advisory Group, highlighting the importance of mentorship and democratizing oncology education worldwide.</p><p>This episode is essential listening for oncologists, trainees, and healthcare professionals navigating the rapidly evolving oncology landscape.</p><p>🔹 Key Topics Covered</p><ul><li><p>Why quality of life should contextualize survival outcomes</p></li><li><p>Gaps in quality-of-life reporting in clinical trials</p></li><li><p>The HemOnc Fellows Network</p></li><li><p>Academic oncology vs community practice</p></li><li><p>Global oncology and trainee mentorship initiatives</p></li><li><p>AI, digital tools, and the future of oncology workflows</p></li><li><p>Advice for trainees considering a career in oncology</p></li></ul><p>🎬A must-watch episode for oncologists, trainees, and healthcare leaders shaping the future of cancer care.</p><p>Connect with Shreyas Kalantri here: <a href="https://www.linkedin.com/in/shreyaskalantrimd/"><u>https://www.linkedin.com/in/shreyaskalantrimd/</u></a> </p><p><br></p><p>📲 Oncology at your fingertips.</p><p>Download the ONCOassist app:</p><p>📥 iOS: <a href="https://apple.co/4iuMxfS"><u>https://apple.co/4iuMxfS</u></a></p><p>📥 Android: <a href="https://bit.ly/oncoassistonandroid"><u>https://bit.ly/oncoassistonandroid</u></a></p><p>📥Webapp: <a href="https://bit.ly/ONCOassistOnWeb"><u>https://bit.ly/ONCOassistOnWeb</u> </a></p><p><br></p><p>📌 FOLLOW US FOR UPDATES: 📍 LinkedIn: <a href="https://bit.ly/oncoassistlinkedin"><u>https://bit.ly/oncoassistlinkedin</u></a></p><p> 📍 Twitter/X: <a href="https://bit.ly/oncoassisttwitter"><u>https://bit.ly/oncoassisttwitter</u></a><br></p>
33 total episodes available
Recent guests on Oncology Spotlight
Guests from recent episodes — sign up to see every guest that has ever appeared on this show.
Dr Paul O'Brien
Guest
Dr Jiten Jaipuria
Guest
Deep-dive analytics for Oncology Spotlight
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Oncology Spotlight?
- How often does this podcast release new episodes?
This podcast updates weekly.
- Where can I listen to this podcast?
This podcast is available on 9 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Yes, this podcast regularly features guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.